369,070 Shares in COMPASS Pathways plc (NASDAQ:CMPS) Bought by Marshall Wace LLP

Marshall Wace LLP purchased a new position in COMPASS Pathways plc (NASDAQ:CMPS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 369,070 shares of the company's stock, valued at approximately $1,395,000. Marshall Wace LLP owned about 0.54% of COMPASS Pathways at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new stake in shares of COMPASS Pathways in the fourth quarter worth $41,000. Wealthfront Advisers LLC bought a new stake in shares of COMPASS Pathways in the fourth quarter worth $43,000. Flagship Harbor Advisors LLC bought a new stake in shares of COMPASS Pathways in the fourth quarter worth $43,000. Conservest Capital Advisors Inc. increased its stake in shares of COMPASS Pathways by 28.9% in the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company's stock worth $51,000 after buying an additional 3,000 shares during the last quarter. Finally, Simplify Asset Management Inc. bought a new stake in shares of COMPASS Pathways in the fourth quarter worth $54,000. Institutional investors own 46.19% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Stifel Nicolaus assumed coverage on shares of COMPASS Pathways in a report on Thursday, February 27th. They issued a "buy" rating and a $11.00 price objective for the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of COMPASS Pathways in a report on Friday, March 28th. Canaccord Genuity Group decreased their price objective on shares of COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a report on Friday, February 28th. HC Wainwright reaffirmed a "buy" rating and issued a $45.00 price objective on shares of COMPASS Pathways in a report on Tuesday, March 4th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $18.00 price objective on shares of COMPASS Pathways in a report on Wednesday, January 15th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $20.20.

COMPASS Pathways Stock Performance

Shares of CMPS opened at $3.88 on Tuesday. COMPASS Pathways plc has a 1 year low of $2.49 and a 1 year high of $9.63. The company has a market cap of $359.57 million, a price-to-earnings ratio of -1.76 and a beta of 2.34. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. The firm has a fifty day moving average of $3.34 and a 200-day moving average of $4.16.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). As a group, equities analysts anticipate that COMPASS Pathways plc will post -2.33 earnings per share for the current year.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.